Ustekinumab: differential use in psoriasis

References

• GelfandJMWeinsteinRPorterSBNeimannALBerlinJAMargolisDJPrevalence and treatment of psoriasis in the United Kingdom: a population-based studyArch Dermatol20051411537154116365254
   PubMed Web of Science ®Google Scholar
• SternRSNijstenTFeldmanSRMargolisDJRolstadTPsoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfactionJ Investig Dermatol Symp Proc20049136139
   PubMed Web of Science ®Google Scholar
• SteinmanLA rush to judgment on Th17J Exp Med20082051517152218591407
   PubMed Web of Science ®Google Scholar
• Mc KenzieBSKasteleinRACuaDJUnderstanding the IL-23-IL-17 immune pathwayTrends Immunol200627172316290228
   PubMed Web of Science ®Google Scholar
• Van den EijndenSGorielySDe WitDIL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in humanEur J Immunol20053546947515682457
   PubMed Web of Science ®Google Scholar
• CaproniMAntigaEMelaniLSerum levels of IL-17 and IL-22 are reduced by etanercept, but not acitretin, in patients with psoriasis: a randomized-controlled trialJ Clin Immunol20092921021418763027
   PubMed Web of Science ®Google Scholar
• LiuHRohowsky-KochanCRegulation of IL-17 in human CCR6+ effector memory T cellsJ Immunol20081807948795718523258
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol200714371972617576937
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMA global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol20051521304131215948997
   PubMed Web of Science ®Google Scholar
• MeasePKivitzABurchFImprovement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a Phase 3 multicenter clinical trialArthritis Rheum200144S90
   Web of Science ®Google Scholar
• YawalkarNKarlenSHungerRExpression of interleukin-12 is increased in psoriatic skinJ Invest Dermatol1998111105310579856816
   PubMed Web of Science ®Google Scholar
• PiskinGSylva-SteenlandRMRBosJDTeunissenMBMIn vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriatic lesions: enhanced expression in psoriatic skinJ Immunol20061761908191516424222
   PubMed Web of Science ®Google Scholar
• CargillMSchrodiSJChangMA large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesAm J Hum Genet20078027329017236132
   PubMed Web of Science ®Google Scholar
• KruegerGGLangelyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med200735658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• GriffithsCEMStroberBFvan de KerkhofPComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med201036211812820071701
   PubMed Web of Science ®Google Scholar
• PariserDMBagelJGelfandJMNational Psoriasis Foundation clinical consensus on disease severityArch Dermatol200714323924217310004
   PubMed Web of Science ®Google Scholar
• MenterAKormanNJElmetsCAGuidelines of care for the management of psoriasis and psoriatic arthritis. Section 5 guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapyJ Am Acad Dermatol20106211413519811850
   PubMed Web of Science ®Google Scholar
• SternRSLairdNThe carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up studyCancer199473275927648194017
   PubMed Web of Science ®Google Scholar
• LeeEKooJBergerTUVB phototherapy and skin cancer risk: a review of the literatureInt J Dermatol20054435536015869531
   PubMed Web of Science ®Google Scholar
• HearnRMKerrACRahimKFFergusonJDaweRSIncidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapyBr J Dermatol200815993193518834483
   PubMed Web of Science ®Google Scholar
• FlytstromIStenbergBSvenssonABergbrantIMMethotrexate versus cyclosporine in psoriasis: effectiveness, quality of life and safety. A randomized controlled trialBr J Dermatol200815811612117986302
   PubMed Web of Science ®Google Scholar
• MenterAKormanNJElmetsCAGuidelines of care for the management of psoriasis and psoriatic arthritis. Section 4 guidelines of care for the management and treatment of psoriasis with traditional systemic agentsJ Am Acad Dermatol20096145148519493586
   PubMed Web of Science ®Google Scholar
• HoVCGriffithsCEAlbrechtGIntermittent short courses of cyclosporin (Neoral[R]) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study; the PISCES study groupBr J Dermatol199914128329110468801
   PubMed Web of Science ®Google Scholar
• UhlenhakeEEFeldmanSREfficacy and safety of ustekinumab and etanercept for the treatment of psoriasisExpert Opin Biol Ther2010101105111220446825
   PubMed Web of Science ®Google Scholar
• Epocrates Rx Pro (iPhone)Ustekinumab Version 3.16.San Mateo, CAEporates Inc2009 Available from http://www.epocrates.com. Accessed April 13, 2011.
   Google Scholar
• Epocrates Rx Pro [iPhone]Etanercept Version 3.16.San Mateo, CAEpocratesInc2009 Available from: http://www.epocrates.com. Accessed April 13, 2011.
   Google Scholar
• Epocrates Rx Pro [iPhone]Adalimumab Version 3.16.San Mateo, CAEpocratesInc2009 Available from: http://www.epocrates.com. Accessed April 13, 2011.
   Google Scholar
• Epocrates Rx Pro [iPhone]Alefacept Version 3.16.San Mateo, CAEpocratesInc2009 Available from: http://www.epocrates.com. Accessed April 13, 2011.
   Google Scholar
• Epocrates Rx Pro [iPhone]Infliximab Version 3.16.San Mateo, CAEpocratesInc2009 Available from: http://www.epocrates.com. Accessed April 13, 2011.
   Google Scholar
• LebwohlMYeildingNSzaparyPImpact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsJ Am Acad Dermatol20106357157920599293
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• KauffmanCLAriaNToichiEA phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisJ Invest Dermatol20041231037104415610511
   PubMed Web of Science ®Google Scholar
• GottliebABCooperKDMc CormickTSA phase 1, double blind, placebo-controlled study evaluating single subcutaneous administration of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisCurr Med Res Opin2007231081109217519075
   PubMed Web of Science ®Google Scholar
• KruegerGGLangelyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med200735658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• PatelRVClarkLNLebwohlMWeinbergJMTreatments for psoriasis and the risk of malignancyJ Am Acad Dermatol2009601001101719344980
   PubMed Web of Science ®Google Scholar
• WeissJMSubleskiJJWiggintonJMWiltroutRHImmunotherapy of cancer by IL-12-based cytokine combinationsExpert Opin Biol Ther200771705172117961093
   PubMed Web of Science ®Google Scholar
• ChienALElderJTEllisCNUstekinumab: a new option in psoriasis therapyDrugs2009691141115219537833
   PubMed Web of Science ®Google Scholar
• ReichKLangleyRGLebwohlMCardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesBr J Dermatol201116486287221332467
   PubMed Web of Science ®Google Scholar
• NiemannALShinDBWangXPrevalence of cardiovascular risk factors in patients with psoriasisJ Am Acad Dermatol20065582983517052489
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimanALShinDBRisk of myocardial infarction in patients with psoriasisJAMA20062961735174117032986
   PubMed Web of Science ®Google Scholar
• GriffithsCEMStroberBEvan de KerkhofPComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med201036211812820071701
   PubMed Web of Science ®Google Scholar
• UhlenhakeEEFeldmanSREfficacy and safety of ustekinumab and etanercept for the treatment of psoriasisExpert Opin Biol Ther2010101819857186
   PubMed Web of Science ®Google Scholar
• ClemmensenASponMSkovLZachariaeCGniadeckiRResponses to ustekinumab in the anti-TNF agent-naive vs anti-TNF agent-exposed patients with psoriasis vulgarisJ Eur Acad Dermatol Venerol2010114
   Google Scholar
• Santos-JuanesJCoto-SeguraPMas-VidalAOsunaCGUstekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumor necrosis factor therapiesBr J Dermatol20101621144114620222926
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet200937363364019217154
   PubMed Web of Science ®Google Scholar
• MartinPLSachsCImaiNDevelopment in the Cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactationBirth Defects Res B Dev Reprod Toxicol20108935136320540088
   PubMed Web of Science ®Google Scholar
• BrodmerkelCZhuYJiaoQEffects of ustekinumab administration on primate/human antigen-recall and humoral immune response functionsJ Drugs Dermatol2010967768320645530
   PubMed Web of Science ®Google Scholar
• VitielloMGrantAKerdelFAUstekinumab: when everything else fails?Int J Dermatol20115047848221413963
   PubMed Web of Science ®Google Scholar
• YeildingNSzaparyPBrodmerkelCDevelopment of the IL-12/IL-23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesAnn N Y Acad Sci20101222303921434940
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol200714371972617576937
   PubMed Web of Science ®Google Scholar
• LangleyMFeldmanSRHanCUstekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trialJ Am Acad Dermatol20106345746520462664
   PubMed Web of Science ®Google Scholar
• LebwohlMPappKHanCUstekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialBr J Dermatol201016213714619903183
   PubMed Web of Science ®Google Scholar
• FowlerJFDuhMSRovbaLThe impact of psoriasis on health care costs and patient work lossJ Am Acad Dermatol20085977278019119095
   PubMed Web of Science ®Google Scholar
• SchaferJKjesboNGleasonPFormulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasisJ Manag Care Pharm20101640241620635831
   PubMed Web of Science ®Google Scholar
• MartinSFeldmanSRAugustinMSzaparyPSchenkelBCost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasisJ Dermatolog Treat20112213814321254886
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol20085882685018423260
   PubMed Web of Science ®Google Scholar